Phase I Study of the Tumor-targeting Human L19IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.

Trial Profile

Phase I Study of the Tumor-targeting Human L19IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Gemcitabine (Primary) ; L19-IL2 fusion protein (Primary)
  • Indications Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Philogen
  • Most Recent Events

    • 24 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2014 to 1 Dec 2015.
    • 12 Oct 2012 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 18 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top